GMS 6540 ALL DRUGS STUDY QUESTIONS AND ANSWERS{WELL COMPOSED}.

MODULE 2 - ANSWER

DNA damaging drugs (2) - ANSWER Cyclophosphamide (DNA alkylating agent)

Cisplatin

Topoisomerase II drugs (2) - ANSWER Doxorubicin, Etoposide

Microtubule drugs (2) - ANSWER Vincristine

Paclitaxel

Antimetabolites (3) - ANSWER Methotrexate5-Fluorouracil (5-FU)Cytosine
arabinoside (Ara C)

Protein tyrosine kinase inhibitors (1) - ANSWER Imatinib

Cyclophosphamide mechanism - ANSWER Alkalating agent; DNA cross links

Haemorrhagic cystitis, Myelosuppression, and secondary malignancies

Cisplatin Mechanism - ANSWER DNA cross-link

Neuro and renal toxicity

Bleomycin Mechanism - ANSWER Free radicals --> DNA breaks

Pulmonary fibrosis

Topotecan Mechanism - ANSWER Topoisomerase I inhibitor

Myelosuppression

Doxorubicin Mechanism - ANSWER Topoisomerase inhibitor II

Myelosuppression and Cardiotoxicity

Etoposide Mechanism - ANSWER Topoisomerase inhibitor II

Myelosuppression

Paclitaxel - ANSWER Microtubule stabilization

Neurotoxicity, myelosuppression

Vincristine Mechanism - ANSWER Disruption of microtubules

Neurotoxicity

Methotrexate Mechanism - ANSWER Folate synthesis inhibitor (DHFR)

, Myelosuppression and Mucositis

F-Fluorouracil Mechanism - ANSWER Folate synthesis inhibitor (TS)

Myelosuppression and Mucositis

Cytarabine Mechanism - ANSWER Inhibit DNA elongations

Myelosuppression

MODULE 3 - ANSWER Targeted Therapy

EGFR Antibodies (6) - ANSWER Cetuximab
Erlotinib/Gefitinib
Gefitinib
Osimertinib
Trastuzumab
Lapatinib

Platelet Derived Growth Factor Receptor - PDGFR - ANSWER Oluratumab
Imatinib

SERMS(2) - ANSWER Tamoxifen
Raloxifene

SERDS (1) - ANSWER Fulvestrant

AIs (1) - ANSWER Anastrozole

Antiandrogens (1) - ANSWER Enzalutamide

Ionizing Radiation (6) - ANSWER Ionizing Radiation
Linear Energy Transfer (LET)
External Beam Radiation
Internal Radiation (Brachytherapy)
Radiosurgery

Cetuximab - ANSWER EGFR treatment binds extracellular domain III
- Blocks EGFR binding
- Induces antibody-dependent cell-mediated cytotoxicity
- ADCC

Erlotinib/Gefitinib - ANSWER EGFR treatment Inhibit ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding

Osimertinib - ANSWER EGFR treatment Inhibits ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding